Rocket Pharmaceuticals Closes $180M PRV Sale, Extends Cash Runway to Q2 2028
RCKT sits 18% above its 52-week low of $2.4.
Summary
Rocket Pharmaceuticals announced the completion of its $180 million sale of a Rare Pediatric Disease Priority Review Voucher, boosting its cash reserves and extending its financial runway.
Key Events · Financing and Capital Events · RCKT
-
Completion of PRV Sale
The company completed the previously disclosed sale of its Rare Pediatric Disease Priority Review Voucher (PRV) on June 10, 2026.
-
Significant Non-Dilutive Proceeds
Rocket Pharmaceuticals received gross proceeds of $180.0 million from the sale, a substantial cash infusion for the company.
-
Extended Cash Runway
The $180 million in proceeds increases pro forma cash, cash equivalents, and investments to approximately $322.6 million, expected to fund operations into the second quarter of 2028.
Analysis · RCKT · Life Sciences
Rocket Pharmaceuticals has completed the sale of its Rare Pediatric Disease Priority Review Voucher, securing $180 million in non-dilutive capital. This substantial cash infusion significantly strengthens the company's balance sheet and extends its operational runway into the second quarter of 2028, providing critical funding for its gene therapy programs following the recent FDA approval of KRESLADI™.
At the time of this filing, RCKT was trading at $2.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $290.5M. The 52-week trading range was $2.40 to $5.45. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.